LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference

Rhea-AI Summary

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that CEO Stephen Hurly will present at the 2021 UBS Global Healthcare Virtual Conference on May 26 at 1:00 p.m. ET. Attendees can access the presentation via the investor relations section of the company’s website. LAVA focuses on developing bispecific gamma-delta T cell engagers aimed at treating solid tumors and hematological malignancies. A Phase 1/2a clinical study for LAVA-051 is expected to yield data in early 2022, and a study for LAVA-1207 in prostate cancer is scheduled for the second half of 2021.

UTRECHT, The Netherlands and PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive officer, will present at the 2021 UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 1:00 p.m. ET.

The presentation will be webcast and can be accessed from the investor relations section of the company's website at www.lavatherapeutics.com.

About LAVA

LAVA Therapeutics N.V. is a clinical stage biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematological malignancies based on its proprietary platform. The company’s innovative approach utilizes bispecific antibodies engineered to selectively kill cancer cells and induce gamma-delta T cell-mediated immunity through activation of Vγ9Vδ2 T cells upon cross-linking to tumor associated antigens. A Phase 1/2a clinical study evaluating LAVA-051 in patients with certain hematologic malignancies is anticipated to generate top line clinical data in the first half of 2022. The Company expects to initiate a Phase 1/2a clinical study to evaluate LAVA-1207 in patients with prostate cancer in the second half of 2021. For more information, please visit www.lavatherapeutics.com.

Contact
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

FAQ

When will LAVA Therapeutics present at the UBS Global Healthcare Conference?

LAVA Therapeutics will present on May 26, 2021, at 1:00 p.m. ET.

How can I access LAVA Therapeutics' presentation?

The presentation can be accessed from the investor relations section of LAVA Therapeutics' website.

What is the focus of LAVA Therapeutics' research?

LAVA Therapeutics focuses on bispecific gamma-delta T cell engagers for treating cancer.

What clinical studies is LAVA Therapeutics currently conducting?

LAVA is conducting Phase 1/2a studies for LAVA-051 and LAVA-1207 in hematological malignancies and prostate cancer, respectively.

What are the expected timelines for LAVA Therapeutics' clinical data?

Top line data for LAVA-051 is anticipated in the first half of 2022.